Boston Scientific Corporation
BSX
$51.24
$0.781.55%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -32.44% | 99.55% | -10.99% | -5.27% | 18.25% |
| Total Depreciation and Amortization | 1.14% | -3.84% | 6.73% | 1.79% | 3.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 132.40% | -349.42% | -14.85% | 352.50% | -136.36% |
| Change in Net Operating Assets | 108.09% | -690.32% | 252.27% | -81.12% | 134.37% |
| Cash from Operations | 323.56% | -74.49% | 1.56% | 4.43% | 137.71% |
| Capital Expenditure | -10.17% | 49.57% | -93.92% | -15.29% | 16.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 62.72% | -487.64% | 65.23% | 74.63% | -322.18% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,536.70% | 251.39% | -10.77% | -262.50% | 154.05% |
| Cash from Investing | -230.96% | -15.43% | -1.99% | 55.42% | -125.20% |
| Total Debt Issued | -- | -- | -- | -100.00% | -99.94% |
| Total Debt Repaid | 94.98% | -23.92% | 2.79% | 31.53% | 76.05% |
| Issuance of Common Stock | -93.83% | 305.00% | -82.61% | 259.38% | -72.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.10% | -1,740.00% | 225.00% | 93.22% | 54.26% |
| Cash from Financing | -57.69% | -41.30% | -76.92% | 69.41% | -245.92% |
| Foreign Exchange rate Adjustments | -- | -- | 250.00% | -200.00% | -94.87% |
| Miscellaneous Cash Flow Adjustments | 200.00% | -- | -- | -- | -- |
| Net Change in Cash | -76.59% | -175.11% | -8.71% | 512.92% | -156.87% |